



THE KIDNEY
CANCER
ASSOCIATION
PRESENTS

IKCS

NORTH AMERICA

**2025 INTERNATIONAL KIDNEY CANCER
SYMPOSIUM: NORTH AMERICA**

Symposium Guide

November 13–15, 2025
Denver, Colorado



About International Kidney Cancer Symposium

The Kidney Cancer Association is proud to host our International Kidney Cancer Symposia in Europe and North America. IKCS meetings are dynamic, multidisciplinary events that explore current trends and future directions in kidney cancer. Our community includes leading experts across academia, clinical care, industry, and advocacy who are committed to exchanging innovative ideas and pushing boundaries to advance kidney cancer care.



JOIN THE CONVERSATION & SHARE YOUR PHOTOS



@kidneycancer



@kidneycancerassociation

KCA THROUGH THE YEARS



1990

KCA FOUNDED

Eugene P. Schonfeld, a kidney cancer patient, collaborated with Dr. Nicholas Vogelzang at the University of Chicago and others to form the National Kidney Cancer Association, eventually the Kidney Cancer Association.

1994

FIRST KIDNEY CANCER LOBBYING EFFORT

Eugene P. Schonfeld lobbied in Washington DC, speaking before Senate and Congress about better care and treatment options for people with kidney cancer. This began the KCA's advocacy efforts.

1995

FIRST KIDNEY CANCER RESEARCH GRANT

The KCA distributes their first research grant, \$30,000, to Dr. Elizabeth Jaffee. Since then, the KCA has given over 60 grants to fund transformational research.

FIRST ANNUAL
★



1999

FIRST KIDNEY CANCER SYMPOSIUM

The first International Kidney Cancer Symposium (IKCS) is held in Chicago, Illinois.

2006

KCA EXPANDS INTERNATIONALLY

The first IKCS in Europe is held in Madrid, Spain, expanding the KCA's international efforts.



2018

NEW DAY AT THE KCA

Gretchen E. Vaughan becomes the KCA's President and CEO, revitalizing the organization's activities and services.



2019

KCA LAUNCHES PATIENT PROGRAMS

New programs include a Just Diagnosed Toolkit, Patient Navigation, support groups, Virtual Patient Symposium, and a Patient Assistance Fund.

2020

THE KCA CELEBRATES ITS 30TH ANNIVERSARY!

2022

NICHOLAS J. VOGELZANG HUMANITARIAN AWARD

In honor of the late co-founder, the KCA established the Nicholas J. Vogelzang Humanitarian Award.



"There was no available treatment for kidney cancer patients in the 80's – literally nothing. It dawned on me that these patients needed a community, a place to share their war stories."
DR. NICHOLAS J. VOGELZANG

2023



KCA LAUNCHES AFFILIATE PARTNER PROGRAM

KCA joins forces with fellow advocacy organizations to expand our collective resources in rare and pediatric kidney cancer.

**CHRIS "CJ" JOHNSON FOUNDATION
COA • HLRCC FOUNDATION
JOEY'S WINGS • JNF KIDNEY CANCER FOUNDATION • WCF**

2024

CELEBRATING 25 YEARS OF IKCS

KCA celebrates milestone 25-year anniversary of International Kidney Cancer Symposium meetings.



2025

RCC ANIMAL MODEL WORKSHOP

The KCA and UT Southwestern Medical Center's Kidney Cancer Research Program co-hosted a groundbreaking workshop for pre-clinical researchers, including two Nobel Prize winners, to accelerate kidney cancer research and bring better treatments and diagnostic tools to patients.



Table of Contents

About the Kidney Cancer Association	5
KCA Staff/ Committee Directory	6
Thank you to the Scientific Planning Committee	8
Welcome Letters	9
2025 IKCS: North America Award Winners	12
Continuing Medical Education Information	13
Program Agenda	15
Keynote Speaker Bio	22
Abstract Poster Listings	24
Exhibitor Map	31
Thank you to our Sponsors	33
Attendee Information	34

JOIN THE CONVERSATION ON X: #IKCSNA25 @KIDNEYCANCER

WIFI INFORMATION

Network: IKCSNA25 **Password:** unstoppabletogether

SYMPOSIUM APP AVAILABLE

Download app and search for "IKCS"



SPONSORED BY



REGISTRATION DESK HOURS

Thursday, Nov 13 1:00PM–7:00PM

Friday, Nov 14 7:00AM–6:00PM

Saturday, Nov 15 7:30 AM - 1:30 PM

About the KCA

The Kidney Cancer Association was founded in 1990 by Eugene P. Schonfeld and a small group of patients and doctors in Chicago, Illinois, and has grown into an international non-profit organization. The KCA promotes scientific advances through two annual research symposiums and a robust grant program, participates in legislative advocacy, and seeks to be a source of education and resources for patients, caregivers, and anyone impacted by kidney cancer.

OUR VISION

To be the universal leader in finding the cure for kidney cancer.

OUR MISSION

To be a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education.

Mail Donations To

Please send donations to our secure lock-box:

ADDRESS

Kidney Cancer Association
PO Box 676226
Dallas, TX 75267-6226

PHONE

USA: (800) 850-9132
INT'L: +1 847 332 1051

EMAIL

donations@kidneycancer.org



KCA STAFF

Gretchen E. Vaughan
President & CEO
Houston, Texas

Salvatore La Rosa, PhD
Chief Scientific Officer
Miami, FL

Kendall Monroe
Chief Advancement Officer
Houston, Texas

Ryan Cerezo
Development Manager
Lathrop, California

Radha Chitale
Senior Director of Communications
Washington, D.C.

Rosemary Chustak
Patient Liaison
Milwaukee, Wisconsin

Gabriela Galvan
Program Coordinator
Houston, Texas

Christine Kelly-Weaver
Office Manager/Executive Assistant
Houston, Texas

Melissa Lopez
Gift Operations Associate
Punta Gorda, Florida

Amy Marbaugh
Director of Patient Programs
Washington, DC

Stephanie Shirley
Director of Advancement Services
(contractor)
Harrisburg, Pennsylvania

Jeanette Stensgaard, MBA, CMP
Director of Events (contractor)
Denver, Colorado

Sarah Tuck
Senior Manager of Patient Programs
Holland, Pennsylvania

Maggie Valdes
Manager of Corporate Partnerships
Houston, Texas

Angela Washington
Director of Operations
Houston, Texas

Sarah Wood
Clinical Engagement Coordinator
Houston, Texas

BOARD OF DIRECTORS

Bradley C. Leibovich, MD
(Chairperson)
Ryan Natzke (Vice Chair)
Tessa Churchill, MD, MBA (Secretary)
Joel Stern (Treasurer)
Laurence Albiges, MD, PhD
Mahul B. Amin, MD
Ronald M. Bukowski, MD
Noah Buntman
Craig DePriester
Daniel J. George, MD
Jamie Graves
David Perry, Esq.
Shelley Robson
Brian Shuch, MD
Gretchen E. Vaughan
Laura S. Wood, RN, MSN, OCN
Ruben Ybarra

CLINICAL ADVISORY BOARD

Laura S. Wood, RN, MSN, OCN
(Chair)
Julia Batten, APRN, MSN, MPH
Sarah Benitez, LCSW OSW-C
Jessica P. Cheng, MSN, APRN, FNP-C
Reena Cherry, MS, PA-C
Patricia Fischer, RN, MSN, OCN
(Emeritus)
Jan Jackson, RN
Zita Lim, PA-C
Lidia Lopez, DNP, MBA
Nancy Moldawer, RN, MSN (Emeritus)
Sweta Patel, BSN, RN, OCN
Renata Penafiel PA-C, MPAS
Virginia J. Seery, MSN, RN, ANP-BC
Julia Stevens, PharmD, BCOP
Emily Wang, PharmD, BCOP
Nazy Zomorodian, NP

MEDICAL STEERING COMMITTEE

Daniel J. George, MD (Chairperson)
Brian Shuch, MD (Vice Chair)
Laurence Albiges, MD, PhD
Mahul B. Amin, MD
Axel Bex, MD, PhD
Ronald M. Bukowski, MD (Emeritus)
Matthew Campbell, MD, MS
Jose A. Karam, MD, FACS
Bradley C. Leibovich, MD
Pavlos Msaouel, MD, PhD
Sumanta Pal, MD
Thomas Powels, MBBS, MRCP, MD
Sarah Psutka, MD
Brian Rini, MD, FASCO,
Eric Singer, MD, MA, MS, FACS,
FASCO
Walter M. Stadler, MD, FACP
(Emeritus)
Nizar M. Tannir, MD, FACP
(Emeritus)
Tian Zhang, MD

PATIENT & CAREGIVER ADVISORY COUNCIL

Ryan Natzke (Chair)
Kathleen Campbell
John Farrell
Sean Healy
Bruce Hill
Vineeta Hiranandani
Ritchie Johnson
Matt McClain
Sid Sadler
Annamaria Scaccia
Nicole Scott
Claudia Tatum
Lindsay Walker
Salima Witt
Peggy Zuckerman



Artist rendering; for illustration purposes only.

In RCC, all T3 tumors are characterized by their invasiveness.¹

These tumors extend into structures within or adjacent to the kidney system, including the perirenal fat, the renal vein, the vena cava, or the pelvicalyceal system.^{1,a}

Patients with more invasive tumors are at a higher risk of their cancer returning.²

Identify patients in your practice who have T3 tumors so you can take appropriate action following nephrectomy.

How will you manage your next patient with an invasive T3 tumor?

^aT3 tumors do not extend beyond Gerota's fascia or into the ipsilateral adrenal gland.¹
RCC = renal cell carcinoma.



References: 1. Edge SB, Greene FL, Byrd DR, et al, eds. *Kidney*. In: *AJCC Cancer Staging Manual*. 8th ed. Springer International Publishing; 2017:739–748.
2. Sundaram M, Song Y, Rogerio JW, et al. Clinical and economic burdens of recurrence following nephrectomy for intermediate high- or high-risk renal cell carcinoma: a retrospective analysis of Surveillance, Epidemiology, and End Results-Medicare data. *J Manag Care Spec Pharm*. 2022;28(10):1149–1160. doi:10.18553/jmcp.2022.22133

Copyright © 2025 Merck & Co., Inc., Rahway, NJ, USA and its affiliates.
All rights reserved. US-JRC-01221 08/25



Thank You 2025 IKCS: North America Scientific Planning Committee

We extend our heartfelt gratitude to our dedicated planning committee for their exceptional contributions to this year's symposium. Your commitment and expertise have been invaluable in making this event a success.



Dr. Manoj Bupathi
Co-Chair



Dr. Sarah Psutka
Co-Chair



Dr. Yousef Zakharia
Co-Chair

PLANNING COMMITTEE CO-CHAIRS



Dr. Stephanie Berg



Dr. Maria Carlo



Dr. Dan Geynisman



Dr. Amy Luckenbaugh



Dr. Jodi Maranchie



Virginia Seery, RN,
MSN



Dr. Chad Tang



Dr. Qing Zhang



Welcome to the 2025 IKCS: North America meeting!

I'm proud to have all of you join us in beautiful Denver, Colorado for this premier gathering of kidney cancer scientists, clinicians, advocates, and industry leaders. This year's program reflects the incredible momentum in our field spanning translational breakthroughs and innovative clinical applications that are transforming outcomes for patients around the world. As we explore the latest data, share new perspectives, and strengthen partnerships, we are reminded that progress in this field is powered by our shared commitment to curiosity, compassion, and collaboration. We are honored to have Gordon J. Freeman, PhD of the Dana-Farber Cancer Institute as our keynote speaker.

His discovery of PD-L1 and PD-L2 proteins revolutionized cancer treatment through immunotherapy and we would not be in the position we are as a field without his diligent and curious spirit.

This year, we recognize three special career awardees. Dr. Michael A.S. Jewett will receive the Nicholas J. Vogelzang Humanitarian Award for service, leadership, advocacy, and compassion for the kidney cancer community. Dr. E. Jason Abel will receive the Andrew C. Novick Award for excellence in urology care. And Dr. Abhishek Chakraborty will receive the Christopher G Wood Rising Star Award for his talent and commitment to kidney cancer research. Join me in congratulating them!

Be sure to spend time in the Exhibit Hall, attend industry symposia, network with friends, and collect your CME credits after IKCS is over.

Our thanks to those working behind the scenes to help us host IKCS. This includes our faculty, sponsors, exhibitors, attendees and the scientific planning committee: Dr. Manoj Bupathi (Co-chair), Dr. Sarah Psutka (Co-chair), Dr. Yousef Zakharia (Co-chair), Dr. Stephanie Berg, Dr. Maria Carlo, Dr. Dan Geynisman, Dr. Amy Luckenbaugh, Dr. Jodi Maranchie, Virginia Seery, RN, MSN, Dr. Chad Tang, and Dr. Qing Zhang.

More than ever before, we recognize the collective benefits of sharing our talents, our passion, and our commitment to excellence in research and clinical care in order to move the needle for people faced with a kidney cancer diagnosis. I'm proud of the KCA's work to support this community and very grateful for the enthusiasm and dedication in return, as evident by everyone's presence at this meeting. I wish you all a productive, inspiring meeting and to remember that, together, we're unstoppable!

Gretchen E. Vaughan
President & CEO, Kidney Cancer Association



Dear International Kidney Cancer Symposium Attendees, welcome to the Mile High City!

We are thrilled to host your Symposium here in the Denver metro area. I know our community is thrilled to have you in town and will be eager to assist you during your stay.


We are honored to welcome leading experts across academia, clinical care, industry, and advocacy who are dedicated to advancing kidney care for all. This Symposium and the opportunity to exchange ideas, share best practices and strengthen professional connections is vital to advancing the essential work you do every day.

The Mile High City offers a unique backdrop for your gathering, and we invite you to enjoy everything the surrounding area has to offer during your stay. From our vibrant and unique neighborhoods to our world-class museums and music venues, as well as the city's culinary offerings, featuring James Beard Award-winning chefs, Michelin-recognized restaurants, gourmet marketplaces and a focus on locally sourced cuisine.

If there is anything we can do to help make your trip more successful, please do not hesitate to reach out to our team at Visit Denver. On behalf of the people of Denver, thank you for the impact you make in your communities.

Respectfully,

Richard W. Scharf
President & CEO, VISIT DENVER





Discover what's possible
with LENVIMA[®]

VISIT OUR BOOTH

 **LENVIMA[®]**
(lenvatinib) capsules | 10 mg and 4 mg



LENVIMA[®] is a registered trademark used by Eisai Inc. under license from Eisai R&D Management Co., Ltd.
© 2025 Eisai Inc. All rights reserved. August 2025 LENV-US12102

2025 IKCS: North America Career Award Recipients



Christopher G. Wood Rising Star Award | Nov 14, 4:45pm

Dr. Abhishek Chakraborty, PhD, *Cleveland Clinic Lerner Research Institute*

Dr. Chakraborty completed his undergraduate (B.Sc) and Masters (M.Sc) degrees in India. He came to the USA for graduate studies at Cold Spring Harbor Laboratory, as a student in the joint program with Stony Brook University and studied the importance of Myc proteolysis in blood cancer. For his post-doctoral research, he moved to Boston, and trained under Dr. William Kaelin at the Dana-Farber Cancer Institute/Harvard Medical School. Dr. Chakraborty's scientific interests include understanding the epigenetic and metabolic perturbations imposed by dysfunctional oxygen-sensing pathways. Dr. Chakraborty's laboratory at the Cleveland Clinic has leveraged these vulnerabilities to discover novel actionable targets in kidney cancer using both animal and human models.



Nicholas J. Vogelzang Humanitarian Award | Nov 15, 11:50am

Dr. Michael A. S. Jewett, MD, FRCSC, FACS, CM, *University of Toronto*

Dr. Michael Jewett receives the Nicholas J. Vogelzang Humanitarian Award, named in honor of the KCA's late co-founder and Board member, for outstanding service and compassion to his patients, colleagues, the KCA, and the wider kidney cancer community. He also received the KCA's Andrew C. Novick Award in 2019 for excellence in urology care.

Dr. Jewett is a Professor of Surgery (Urology) at the Princess Margaret Cancer Centre and at the University of Toronto. He is also the immediate past chair of the International Kidney Cancer Coalition's Board of Directors and Medical Advisory Board. For his "life-saving innovations in surgical oncology and for his advocacy of patient-centred critical care," Dr. Jewett was appointed to the Order of Canada, one of the country's highest civilian honors.



Andrew C. Novick Award, Nov 15, 1:40pm

Dr. E. Jason Abel, MD, FACS, *University of Wisconsin*

Dr. E. Jason Abel is the Chief of Urologic Oncology, Professor of Urology and Radiology, and the Robert F. and Dolores K Schnoes Chair in Urologic Research at the University of Wisconsin School of Medicine and Public Health. The Novick award recognizes healthcare professionals who have made significant contributions over the course of their careers in urology for the treatment of kidney cancer.

Continuing Medical Education Information



This activity is jointly provided by The France Foundation and the Kidney Cancer Association

TARGET AUDIENCE

This educational activity is intended for medical oncologists and urologists who treat patients with kidney cancer. Fellows, trainees, nurses, nurse practitioners, physician assistants, and other healthcare professionals involved in the management of kidney cancer are invited to participate.

STATEMENT OF NEED

Education and interaction surrounding the space of renal cell carcinoma are paramount to improving patient care. This program is targeted to physicians, advocates, and researchers to help promote learning and collaboration for advancement in the renal cancer space.

EDUCATIONAL ACTIVITY LEARNING OBJECTIVES

Upon completion of this course, the participants should be able to:

- Characterize the various therapies currently available for locally advanced and metastatic renal cell carcinoma
- Identify the novel approaches to non-clear RCC patient management
- Understand the role of the tumor microenvironment in kidney cancer
- Discuss how to design biomarker driven clinical trials in kidney cancer

ACCREDITATION STATEMENT

In support of improving patient care, this activity has been planned and implemented by The France Foundation and the Kidney Cancer Association. The France Foundation is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.



CREDIT DESIGNATION

Physicians: The France Foundation designates this live activity for a maximum of 14.0 AMA PRA Category 1 Credit(s)[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.



Nurses: The France Foundation designates this activity for 14.0 ANCC contact hours.



Physician Assistants: The France Foundation has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 14.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.



All other health care professionals completing this course will be issued a statement of participation.

METHOD OF PARTICIPATION/ HOW TO RECEIVE CREDIT

1. Review the activity objectives and CME/CE information.
2. Participate in the CME/CE activity.
3. TO CLAIM CREDIT

Complete the course evaluation which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.

CLAIM CREDIT

Scan QR Code to take the course evaluation



4. If you are requesting educational credits or a certificate of participation, your certificate will be available for download.

DISCLOSURE POLICY

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) and the Kidney Cancer Association (KCA) require that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF and the KCA resolve all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all their educational programs. Furthermore, TFF and KCA see to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF and KCA are committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Scan QR code to view disclosures for all IKCSNA Planners and Faculty.



DISCLOSURE OF UNLABELED USE

TFF and KCA require CME faculty (speakers) to disclose when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion.

Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration-approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF and KCA do not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

DISCLAIMER

TFF and KCA present this information for educational purposes only. The content is provided solely by faculty who have been selected because of their recognized expertise in their field. Participants have the professional responsibility to ensure that products are prescribed and used appropriately on the basis of their own clinical judgment and accepted standards of care. The France Foundation, KCA, and the commercial supporter(s) assume no liability for the information herein.

SOURCES OF FUNDING

Funding sources supporting this conference include the following:

- Participants' registration fees
- Exhibition booths during the event
- Industry symposia offered ancillary to the event (not eligible for CME credit)
- Advertisements outside the scientific program

INFORMATION

If you have questions about this CME/CE activity, please contact The France Foundation at **860-434-1650** or asmeaton@francefoundation.com

Meeting Agenda

WEDNESDAY, NOVEMBER 12, 2025

2:00PM–6:00PM **KCA Mentorship Academy** (by invitation only)
Flat Irons Moderator: Salvatore La Rosa, PhD

THURSDAY, NOVEMBER 13, 2025

8:00AM–11:00AM **KCA Mentorship Academy** (by invitation only)
Flat Irons Moderator: Salvatore La Rosa, PhD

12:00PM–3:45PM **Academy of Kidney Cancer Investigators (AKCI) Mentorship Meeting** (by invitation only)
Flat Irons Moderator: Brian Rini, MD, FASCO

12:30PM–3:30PM **KCA Think Tank Session Sponsored by Exelixis** (by invitation only)
Cotton Creek I-II Moderators: Pavlos Msaouel, MD, PhD and Martin Voss, MD

1:00PM–7:30PM **Registration Open**

3:45PM–4:45PM
Westminster Ballroom I-III

Pre-Clinical Session 1: Kidney Cancer Immunotherapy - The Next Front
Moderator: Qing Zhang, PhD

Multifunctional Nanoparticles in Immunotherapeutics for Kidney Cancer • Andrew Wang, MD
Neoantigen Vaccine Therapy in RCC • David Braun, MD, PhD

Recognizing the Role of Tumor-Immune Interactions in Pre-clinical Target Discovery in RCC • Abhishek Chakraborty, PhD

Immune Checkpoint Inhibitors in Metastatic RCC: Lessons Learned from Clinics • Sangeeta Goswami, MD, PhD

Anti-Tumor Efficacy of SPOP Inhibition to Combine with Immunotherapy Through Stabilizing and Activating STING • Pengda Liu, PhD

Pre-Conference Session Q&A • Qing Zhang, PhD

4:50PM–5:50PM
Westminster Ballroom I-III

Pre-Clinical Session 2: Non-Clear Cell Kidney Cancer
Moderator: Lisa Henske, MD

Chromophobe RCC: From Pathogenesis to Therapy • Lisa Henske, MD

Translocation RCC: From Mouse Modeling to Therapy • James Brugarolas, MD, PhD

Therapeutic Targeting of Translocation Renal Cell Carcinoma • Srinivas Viswanathan, MD, PhD

Modeling RMC: Elucidating Pathogenesis and Uncovering Therapeutic Vulnerabilities • Pavlos Msaouel, MD, PhD

Targeting Metabolic Reprogramming in Birt Hogg Dubé Syndrome Associated Renal Cancer • Mehdi Mollapour, PhD

Pre-Conference Session Q&A • Lisa Henske, MD

THURSDAY, NOVEMBER 13, 2025 (CONTINUED)

5:55PM–6:55PM
Westminster Ballroom I–III

Localized Treatments for Kidney Cancer Workshop
Moderators: Daniel Shapiro, MD, FACS & Chad Tang, MD

Localized RCC with Tumor Thrombus • Dan Shapiro, MD
Metastatic RCC with Duodenal Infiltration (Non-Surgical Candidate) • Jinzhong Yang, PhD
Oligometastatic Metachronous Recurrence • Chad Tang, MD
Synchronous Metastatic RCC • Stephanie Berg, MD
Workshop Q&A • Dan Shapiro, MD & Chad Tang, MD

7:30PM–10:00PM
Scratch Golf Lounge

IKCSNA25 Faculty Networking Night Sponsored by Aveo Oncology (by invitation only)
Transportation runs every 20 mins to and from venue.

FRIDAY, NOVEMBER 14, 2025

7:00AM–6:00AM

Registration Open

7:00AM–8:00AM
Westminster Ballroom IV

Young Investigators Session & Breakfast sponsored by Pfizer
Moderators: Nazli Dizman, MD & Dan George, MD

Young Investigators Session Chair Welcome • Nazli Dizman, MD & Dan George, MD
A Word From Our Sponsor • S. Hariharan, MD, FACP
Mentor/ Mentee Discussion • Brian Shuch, MD, Allison May, MD, Brian Rini, MD, FASCO, Wesley Yip, MD, Abhishek Chakraborty, PhD, Treg Grubb, PhD

8:15AM–9:25AM
Westminster Ballroom I–III

SESSION 1

Welcome to the Conference: Kicking Off with Kidney Cancer Controversies
Moderator: Sarah Psutka, MD, Msc & Yousef Zakharia, MD

Patient Case • Yousef Zakharia, MD
PET Imaging in RCC, the Old and the New • Aradhana Venkatesan, MD
Defining the Limit of Surgical Resectability in Locally Advanced Disease • Jason Abel, MD, FACS
Frontline Systemic Therapy in the Era of Adjuvant Therapy • Andy Hahn, MD
Current Clinical Trials in Oligometastatic Disease • Ben Garmez, MD
Session 1 Q&A • Sarah Psutka, MD, Msc & Yousef Zakharia, MD

FRIDAY, NOVEMBER 14, 2025 (CONTINUED)

9:25AM–10:25AM

Westminster Ballroom I–III

SESSION 2

Breaking Down Barriers: Navigating the Regulatory Process Clinical Trials

Moderators: Ulka Vaishampayan, MBBS & Tian Zhang, MD

How to Make Clinical Trials More Efficient: Streamlining Clinical Trial Activation (Teaching the Model How to Do This) • Manoj Bupathi, MD, PhD

Creating a Balanced Clinical Trial Portfolio • Sumanta K Pal, MD, FASCO

AI Utilization in Clinical Trials Activation and Process • Irbaz Riaz, MD, PhD

Creating a Cancer Trial Network • Eric Jonasch, MD

Registration Success-Navigating Pharma/FDA Pathways • Ulka Vaishampayan, MBBS

Session 2 Q&A • Ulka Vaishampayan, MBBS & Tian Zhang, MD

10:25AM–10:50AM

Legacy Ballroom

Snack and Beverage Break with Exhibitors in Exhibit and Poster Hall

Need a break? You gotta be kidney me! Head to the Exhibit Hall and get a refresher!

10:50AM–11:55AM

Westminster Ballroom I–III

SESSION 3

Patient-Centric Care

Moderators: Katie Coleman & Amy Luckenbaugh, MD, FACS

Congratulations to KCA Mentorship Academy & Mentorship • Gretchen E. Vaughan, S. Hariharan, MD, FACP, Salvatore La Rosa, PhD & Eric Singer, MD, MA, MS

Patient Vignette • Teri Wight

Cure vs. Consumed • Dena Battle

Current Research on Nutrition • Michael Staehler, MD, PhD

Overcoming Cognitive Effects of Treatment Burden • David Sheppard, PhD

Hard-to-Treat Adverse Events with TKI Therapy • Dan Geynisman, MD

Session 3 Q&A • Katie Coleman & Amy Luckenbaugh, MD, FACS

11:55AM–12:55PM

Westminster Ballroom I–III

SESSION 4

AYA Kidney Tumors

Moderators: Candace Granberg, MD & Nicholas Cost, MD

Patient Vignette • Kim Frederking

AYA Population • Candace Granberg, MD

AYA Wilms Tumors • Michael Ortiz, MD

Managing VHL in Adolescents and Young Adults • Jodi Maranchie, MD

Long-Term Side Effects • Nicholas Cost, MD

Session 4 Q&A • Candace Granberg, MD & Nicholas Cost, MD

12:55PM–2:10PM

Legacy Ballroom

Lunch with Exhibitors in Exhibit and Poster Hall

“Urine” for more insight — pick up lunch, connect with exhibitors, and head over to the Industry Symposium in Westminster Ballroom IV, for a full plate of progress!

FRIDAY, NOVEMBER 14, 2025 (CONTINUED)

1:05PM–2:05PM
Westminster Ballroom IV

Industry Sponsored Session: IKCS Biotech Power Hour 
Moderator: Michele Oshman, Chief Patient Advocate, *Biotechnology Innovation Organization*

Fireside Chats with Biotech Leaders

Kim Allman, MSN, CNP, AOCNP, *Telix Pharmaceuticals*
Richard Markus, MD, PhD, *Arcus Biosciences*
Dale Muzzey, PhD, *Myriad Genetics*
Rod Humerickhouse, MD, PhD, *Xencor*
Börje Haraldsson, MD, PhD, FASN, FAST, *Oncorena*

2:10PM–3:10PM
Westminster Ballroom I-III

SESSION 5
Oral Abstract Session
Moderators: Stephanie Berg, DO & Adam Singer, MD

Awards Presentation • Dan Geynisman, MD

Poster Ad #1: Cabozantinib in Patients (Pts) With Non-Locally Pretreated Brain Metastases (BM) From Renal Cell Carcinoma (RCC): Results From the Multicenter CABRAMET Phase II Trial • Sylvie Negrier, MD, PhD

Poster Ad #2: Association Between Wildfire-Dominated PM2.5 Exposure and Renal Cell Carcinoma Survival in California • Shuchi Gulati, MD, MSc

Poster Ad #3: AI-Driven Multiplex Immunofluorescence Analysis of the Tumor Immune Microenvironment to Predict Immunotherapy Response in Clear Cell Renal Cell Carcinoma • Yuanquan Yang, MD, PhD

Poster Ad #4: Strategic Trimodal Therapy Enhances Radiation-Induced Abscopal Response in Renal Cancer
Krishnendu Pal, PhD

Oral Abstract Presentation #1: A Multi-Institution Analysis of Outcomes for 190 Patients With Metastatic Chromophobe Renal Cell Carcinoma With and Without Sarcomatoid Features • Sahil Doshi, MD

Oral Abstract Presentation #2: Outcomes of Patients With Fumarate Hydratase-Deficient Renal Cell Carcinoma Treated With Cabozantinib + Nivolumab • Maria Carlo, MD

Oral Abstract Presentation #3: Exploring the Impact of Combined Anti-Angiogenic and Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma Metastases • Stefan Maksimovic, MD

Oral Abstract Presentation #4: Preliminary Phase 1 Safety and Antitumor Activity of XmAb819, a First-in-Class ENPP3 x CD3 Bispecific Antibody, in Patients With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) • Sumanta Kumar Pal, MD, FASCO

Session 5 Q&A • Stephanie Berg, DO & Adam Singer, MD

3:10PM–3:40PM
Westminster Ballroom I-III

SESSION 6
Keynote
Moderator: Manoj Bupathi, MD, MS

Keynote Speaker: PD-1 / PDL-1 / T-Cel Activation/ Signaling • Gordon J. Freeman, PhD

3:40PM–4:00PM
Legacy Ballroom

Snack and Beverage Break with Exhibitors in Exhibit and Poster Hall

Still processing that Keynote? Let it flow — swing by the Exhibit Hall for refreshment and one last chat with our fabulous exhibitors!

FRIDAY, NOVEMBER 14, 2025 (CONTINUED)

4:00PM–4:45PM

Westminster Ballroom I–III

SESSION 7

AKCI Mentorship Session

Moderator: Brian Rini, MD, FASCO

Investigating the Immunomodulatory Effects of Chemokine Signaling in Localized Renal Cell Carcinoma

Daniel Shapiro, MD, FACS

Profilin1's Role in Chromophobe Renal Cell Carcinoma • David Gau, PhD

Session 7 Q&A • Brian Rini, MD, FASCO

4:45PM–5:05PM

Westminster Ballroom I–III

SESSION 8

Christopher G. Wood Rising Star Award

Christopher G. Wood Rising Star Award: Introduction to Award Recipient • Brian Rini, MD, FASCO

Christopher G. Wood Rising Star Award: Recipient Lecture • Abhishek A. Chakraborty, PhD

5:05PM–5:45PM

Westminster Ballroom I–III

SESSION 9

Optimizing Immunotherapy Delivery in Kidney Cancer: Implementation Insights for the Care Team

Moderator: Ulka Vaishampayan, MBBS

Welcome and Background Presentation • Ulka Vaishampayan, MBBS

Patient Perspective • Keith Clem

Panel Discussion: Implementation Insights and Challenges • Saby George, MD, Katy Beckermann, MD, Ben Garmezy, MD

Session 9 Q&A • Ulka Vaishampayan, MBBS

5:45PM–6:45PM

Westminster Ballroom I–III

SESSION 10

How Do You Select 2nd, 3rd, 4th Line Therapies in Kidney Cancer

Moderators: Laurence Albiges, MD, PhD & Wesley Yip, MD

Approach to Clear Cell RCC When First-Line Therapies Fail • Arpita Desai, MD

Novel Approaches to Chromophobe RCC- When First-Line Therapies Fail • Lisa Henske, MD

Approach to Nonclear-Cell RCC When First-Line Therapies Fail • Martin Voss, MD

Oligo Progression – Should We Switch Therapies or Elect Metastasis-Directed Therapy? • Anand Swaminath, MD

Session 10 Q&A • Laurence Albiges, MD, PhD & Wesley Yip, MD

6:45PM–7:45PM

Legacy Ballroom

Evening Networking Reception

From research to refreshments — connect with exhibitors, browse posters, and toast to the future of kidney cancer care!

7:00PM–7:30PM

Legacy Ballroom

Guided Poster Tours • Maria Carlo, MD & Chad Tang, MD

Posters, peers, and progress — join a guided tour to hear the research straight from the source.

SATURDAY, NOVEMBER 15, 2025

6:15AM–7:00AM

Longs Peak

Sunrise Yoga • with Innovative Yogis' Yogi Brett Engle

Start your morning with purpose and peace. Join us for Innovative Yogis for a sunrise yoga session where every deep breath and gentle stretch helps shine light on kidney cancer awareness. Breathe in hope, exhale stress, and flow toward something bigger.

6:15AM–7:00AM

Meet in front lobby

Real Steps Toward a Cure Fun Run – sponsored by Eisai • with Innovative Yogis' Yogi, Kimberly Hidalgo

Ready to make real strides in the fight against kidney cancer? Join us for "Real Steps Toward a Cure" — the not-so-average morning run where science meets sneakers. It's fun, it's fast(ish), and yes... you might just hear someone yell, "Catch me? You gotta be kidney me!" Lace up, laugh a little, and let's run toward something bigger.

7:00AM–8:00AM

Flat Irons

KCA Medical Steering Committee Meeting (by invitation only)

Moderators: Salvatore La Rosa, PhD

7:30AM–1:30PM

Registration Open

7:45AM–9:00AM

Westminster Ballroom IV

Women in RCC Breakfast & Education sponsored by Pfizer and Exelixis

Moderators: Ulka Vaishampayan, MBBS & Tian Zhang, MD

Networking Breakfast

Keynote: The Energy Shift: Your Competitive Edge in Work and in Life • Natalie Johnson, MS

Moderated Q&A • Ulka Vaishampayan, MBBS & Tian Zhang, MD

9:15AM–9:35AM

Westminster Ballroom I–III

SESSION 11

Day 2 Welcome and KCA Updates

Moderator: Sarah Psutka, MD, MSc & Yousef Zakharia, MD

Recap of Day 1 • Sarah Psutka, MD, MSc & Yousef Zakharia, MD

KCA Updates • Salvatore La Rosa, PhD

Committee Recognition • Gretchen E. Vaughan & Salvatore La Rosa, PhD

9:35AM–10:35AM

Westminster Ballroom I–III

SESSION 12

Methods and Novel Trial Design Cancer Controversies

Moderator: Pavlos Msaouel, MD, PhD & Brian Shuch, MD

Optimizing Statistical Methodology; Novel Trial Design • Ruitao Lin, PhD

Rethinking Recently Published Trials- Are We Interpreting Them Correctly • Daniel Shapiro, MD, FACS

Strategies to Partner With Industry on Design and Conduct of Clinical Trials • Laurence Albiges, MD, PhD

PDIGREE Implementation: Lessons Learned from a Large NCTN Trial • Tian Zhang, MD

Session 12 Q&A • Pavlos Msaouel, MD, PhD & Brian Shuch, MD

10:35AM–11:35AM

Westminster Ballroom I–III

SESSION 13

Ongoing Clinical Trials and Considerations in a Refractory Setting

Moderator: Kathryn Gessner, MD, PhD & Minas Economides, MD

Immunotherapy Trials • Pedro Barata, MD

Ongoing Targeted Therapy Trials • Martin Voss, MD

Cellular Therapy Trials • Pavlos Msaouel, MD, PhD

Image Guided Therapy Trials • Rahul Sheth, MD, FSIR

Identifying Hidden Targets for Future Trials • David Braun, MD, PhD

Session 13 Q&A • Kathryn Gessner, MD, PhD & Minas Economides, MD

SATURDAY, NOVEMBER 15, 2025 (CONTINUED)

11:30AM–11:50AM

Legacy Ballroom

Snack and Beverage Break with Exhibitors in Exhibit and Poster Hall

It's your final flush! Grab a snack, say hi to exhibitors, and let's wrap this up with a strong stream of science!

11:50AM–12:10PM

Westminster Ballroom I–III

SESSION 14

Nicholas J. Vogelzang Humanitarian Award 

Nicholas J. Vogelzang Humanitarian Award: Introduction of Recipient • Eric Jonasch, MD
Nicholas J. Vogelzang Humanitarian Award: Recipient Lecture • Michael A. S. Jewett, MD, FRCSC, FACS, CM

12:10PM–1:10PM

Westminster Ballroom I–III

SESSION 15

Advances in Translational Science - Using Biomarkers to Select Therapy

Moderator: Nazli Dizman, MD & Eric Singer, MD, MA, MS

Novel Biomarkers: Hit It From Translational • Adam Kase, MD
The Role of Liquid Biopsy in Renal Cancer • Arnab Basu, MBBS, MPH
KIM-1; Are We Getting Close to Prime Time • Wenxin (Vincent) Xu, MD
Next-Gen RCC Gene Expression Signatures: Using RNAseq to Guide Therapeutic Decisions • Scott Haake, MD, PhD
Session 15 Q&A • Nazli Dizman, MD & Eric Singer, MD, MA, MS

1:10PM–1:40PM

Westminster
Foyer

Grab a Boxed Lunch – Eat & Explore, Back to Session in 30 Min

Lunch break! Grab your boxed lunch, mingle a bit, and squeeze in a personal pit stop before we stream back into session.

1:40PM–2:00PM

Westminster Ballroom I–III

SESSION 16

Andrew C. Novick Award 

Andrew C. Novick Award: Introduction of Award Recipient • Viraj Master, MD, PhD, FACS
The Nicholas J. Vogelzang Humanitarian Award: Award Recipient Lecture • E. Jason Abel, MD, FACS

2:00PM–2:45PM

Westminster Ballroom I–III

SESSION 17

WoodFire

Moderator: Dan Geynisman, MD & Robert G. Uzzo, MD, MBA, FACS

WoodFire Panel discussion • Allision May, MD, Chad Tang, MD, Fed Ghali, MD, Pedro Barata, MD, Jodi Maranchie, MD

2:45PM–3:00PM

Westminster Ballroom I–III

Closing Remarks • Sarah Psutka, MD, Msc, Yousef Zakharia, MD, Manoj Bupathi, MD, MS



Keynote Speaker: Gordon J. Freeman, PhD

Professor of Medicine, Dana-Farber Cancer Institute and Harvard Medical School

Gordon J. Freeman, PhD is renowned for discovering the PD-L1 and PD-L2 proteins. Dr. Freeman showed that PD-L1 and PD-L2 bound to PD-1 to turn off the immune response and that blockade of PD-L1/PD-1 enhanced immune responses. He further showed that PD-L1 is highly expressed on many tumors and allows these tumors to resist immune attack. Dr. Freeman's work led directly to the development of a successful strategy for cancer immunotherapy - blocking the PD-1-ligand interaction. Dr. Freeman has published over 400 scientific papers and holds over 90 US patents on immunotherapies. He was elected to the National Academy of Sciences and the National Academy of Inventors, is a Fellow of the AACR and SITC Academies, and has received numerous awards, including the William B. Coley Award for Distinguished Research in Tumor Immunology, the Warren Alpert Foundation Prize, and the Richard Smalley, MD, Memorial Award. Dr. Freeman received his Ph.D. degree in Microbiology and Molecular Genetics from Harvard University.



KCA CareLink

KCA CareLink is a free network of benefits and support for clinicians and their patients.

Members can:

- Access expert tools
- Increase your visibility to kidney cancer patients
- Quickly offer patients support resources
- Earn CME credits
- Apply for exclusive grants and mentorship opportunities



Scan QR code to enroll today!



EXPLORE A
BALANCE OF DATA



**ACCESS THE CHECKMATE-9ER
CLINICAL TRIAL RESULTS**
bit.ly/view9ER

CABOMETYXhcp.com

Poster by Track

TRACK	POS #
Basic Science/Tumor Biology/Microenvironment	A1, A2, A3, A4, A5, A6, A7, A8
Disparities in Cancer, Care, and Access	B1, B2, B3, B4
Imaging	C1, C2, C3, C4, C5
Diagnostics	D1
Post-treatment Surveillance	E2
Real-World Evidence	F1, F2, F3, F4, F5, F6, F7, F8, L1, L2
Other	G1, G2, G3, G4, G5, G6, G7
Patient-reported Outcomes	H1
Tumor Biomarkers and Pathology	I1, I2, I3, I4,
Prevention and Screening	J1, J2
Quality of Care and Quality Improvement	K1
Survivorship	M1
Therapeutics	N1, N2, N3, N4, N5, N6, N7, N8
Translational Research	O1, O2, O3, O4, O5, O6

Learn about
KEYTRUDA
and **LENVIMA**

KEYTRUDA[®]
(pembrolizumab) Injection 100 mg



LENVIMA[®]
(lenvatinib) capsules | 10 mg and 4 mg

Explore the data at:
KeytrudaLenvimaHCP.com



Poster Listings

POS #	PRESENTATION TITLE	TRACK	AUTHOR
A1	Drugs resistance mechanisms guided by amino acids catabolism in ccRCC	Basic Science/ Tumor Biology/ Microenvironment	Angela Cappello
A2	BAP1 Deficiency Enhances Spheroid Formation and Metabolic Flexibility in ccRCC via IP3R3 Regulation	Basic Science/ Tumor Biology/ Microenvironment	Carlo Ganini
A3	A multimodal comparison of metabolic profiling methods to explore tumor heterogeneity with single-cell resolution	Basic Science/ Tumor Biology/ Microenvironment	Elijah Kofke
A4	TRIP13 is upregulated in aggressive chromophobe renal cell carcinoma and may be a promising therapeutic target	Basic Science/ Tumor Biology/ Microenvironment	Elizabeth Ellis
A5	Association of G-coupled protein receptor 65 (GPR65), a novel therapeutic target, with immunotherapy response in metastatic renal cell carcinoma (mRCC)	Basic Science/ Tumor Biology/ Microenvironment	Koral Shah
A6	Higher ectonucleotide pyrophosphate/phosphodiesterase 3 (ENPP3) expression in patients with metastatic renal cell carcinoma (mRCC) is associated with an angiogenic subtype	Basic Science/ Tumor Biology/ Microenvironment	Michelle Li
A7	Obesity Attenuates Mitochondrial Dysfunction in Human Clear Cell Renal Cell Carcinoma	Basic Science/ Tumor Biology/ Microenvironment	Precious Oporum
A8	Performance of a validated 15-gene prognostic signature in localized papillary renal cell carcinoma	Basic Science/ Tumor Biology/ Microenvironment	Steven Monda
B1	Equity in Genomic Integration and Outcomes in DDR-Mutant mRCC	Disparities in Cancer, Care, and Access	Aripta Desai
B2	Knowledge Gaps and Shared Decision Making (SDM) Disparities in Kidney Cancer (KC) Across North America (NA): Results from the International Kidney Cancer Coalition (IKCC) Global Patient Survey (GPS)	Disparities in Cancer, Care, and Access	Eric Jonasch
B3	Socioeconomic Disadvantage is Predicted from AI Image Analysis of CT Imaging in Kidney Cancer Patients	Disparities in Cancer, Care, and Access	Gabriela Diaz
B4	Kidney Cancer Trends, Risk Factors, and Interventions in American Indian and Alaska Native Populations.	Disparities in Cancer, Care, and Access	Salvatore La Rosa

POS #	PRESENTATION TITLE	TRACK	AUTHOR
C1	External Validation of AI Age Discrepancy as a Measure of Frailty in Kidney Tumor Patients	Imaging	Nicholas Heller
C2	Pathologic T3 RCC Prediction Using the SHARP (Staging of High-risk And non-metastatic Renal cell carcinoma Preoperatively) Model: A Tool for Preoperative Staging and Neoadjuvant Trial Enrollment	Imaging	Paz Lotan
C3	Artificial Intelligence to Predict Risk of Chronic Kidney Disease Progression After Nephrectomy Based on Preoperative Cross-Sectional Imaging	Imaging	Sahil Patel
C4	External Validation of an AI-Based Automatic Renal Nephrometry Scoring System	Imaging	Sahil Patel
C5	Artificial Intelligence for Predicting Perioperative Outcomes From Preoperative Imaging in Kidney Tumor Patients	Imaging	Jacob Knorr
D1	Predicting Clear Cell Subtype for Kidney Tumors From Cross-Sectional Imaging Using Artificial Intelligence	Diagnostics	Jacob Knorr
E2	Beyond Clear Cell: Rethinking Postoperative Surveillance for Non-clear cell RCC	Post-treatment Surveillance	Arighno Das
F1	Single Institution Analysis of Outcomes in Chromophobe Renal Cell Carcinoma, Oncocytoma, and Oncocytic Neoplasm of Low Malignant Potential	Real-World Evidence	Jacob Knorr
F2	Quality of life (QOL), physician-selected reasons, and starting doses for immuno-oncology (IO)-based systemic therapy (ST) in the ODYSSEY prospective observational study	Real-World Evidence	Michael Harrison
F3	Shifting Treatment Patterns in Chromophobe Renal Cell Carcinoma: A U.S. Real-World Data Analysis	Real-World Evidence	Miguel Zugman
F4	Real world experience with adjuvant pembrolizumab in clear cell renal cell carcinoma (ccRCC).	Real-World Evidence	Mousab Al Abbas
F5	Real-world Study of Treatment Patterns in Heavily Pretreated Metastatic Renal Cell Carcinoma (mRCC) Patients	Real-World Evidence	Neil Shah
F6	Using Large Language Models To Automatically Extract Structured Data From Radiology, Operative, and Pathology Reports for Kidney Tumor Patients	Real-World Evidence	Nicholas Heller

POS #	PRESENTATION TITLE	TRACK	AUTHOR
F7	Real World Evidence of Belzutifan Use in Patients with Von Hippel-Lindau (VHL) Associated Renal Cell Carcinoma (RCC), CNS Hemangioblastoma (CNS-Hb), or Pancreatic Neuroendocrine Tumors (pNETs)	Real-World Evidence	Reshme Shinde
F8	A multi-institution analysis of outcomes for 190 patients with metastatic chromophobe renal cell carcinoma with and without sarcomatoid features	Real-World Evidence	Sahil Doshi
G1	Fumarate hydratase variant prevalence in a reproductive carrier screening population	Other	Brian Shuch
G2	Long-term exposure to ambient fine particulate matter and risk of renal cell cancer in the NIH-AARP Diet and Health Study	Other	Jinhui Li
G3	A phase 1/2, open label, single arm study on safety, tolerability and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell renal cell carcinoma (ccRCC) or papillary renal cell carcinoma (pRCC)	Other	Nizar Tannir
G4	Safety and efficacy of HLA-G-targeted CAR T cell therapy (IVS-3001) in patients with advanced clear cell RCC and other HLA-G-positive solid tumors: Clinical trial in progress	Other	Nizar Tannir
G5	The Translocation Renal Cell Carcinoma Project: Direct Digital Engagement of Patients with a Rare Kidney Cancer	Other	Zoe Geary
G6	Association between wildfire-dominated PM2.5 exposure and renal cell carcinoma survival in California	Other	Shuchi Gulati
G7	Spontaneous Regression of Biopsy-Confirmed Renal Cell Carcinoma Primary Tumors on Active Surveillance- Clinical and Pathologic Correlates	Other	Paz Lotan
H1	Multi-institution Evaluation of Patient versus Urologist Rated Performance Status and Association with Renal Cell Carcinoma Surgical Outcomes	Patient-reported Outcomes	Paz Lotan
I1	AI-empowered Cellular Morphometric Biomarkers predict treatment response and prognosis in clear cell renal cell carcinoma	Tumor Biomarkers and Pathology	Shuchi Gulati
I2	A decision-making tool for first-line treatment selection in metastatic renal cell carcinoma based on plasma proteomics	Tumor Biomarkers and Pathology	Clara Steiner
I3	Enriched YES1 tumor expression at the stromal interface is associated with worse overall survival in clear cell renal cell carcinoma when treated with first-line immune checkpoint blockade	Tumor Biomarkers and Pathology	Mitchell Hayes
I4	Cluster of differentiation 70 (CD70) is associated with an angiogenic subtype in patients with metastatic renal cell carcinoma (mRCC)	Tumor Biomarkers and Pathology	Vitor Abreu de Goes

POS #	PRESENTATION TITLE	TRACK	AUTHOR
J1	Associations of abdominal adiposity and skeletal muscle with renal cell carcinoma histological subtype, grade, and stage	Prevention and Screening	Ken Batai
J2	Impact of Post-Diagnosis Body Mass Index (BMI) Change on Survival in Localized Renal Cell Carcinoma	Prevention and Screening	Monica Sarker
K1	Factors Associated with IVC Thrombectomy for Non-Metastatic, Node-Negative Renal Cell Carcinoma in Octogenarians	Quality of Care and Quality Improvement	Rajvi Goradia
L1	Efficacy and Safety of Bevacizumab plus Everolimus in Pretreated Metastatic non-clear cell RCC	Real-World Evidence	Antonio Ocejó
L2	Local recurrence after nephron-sparing treatment of renal cell carcinoma – a risk factor for metastases and early death	Real-World Evidence	Borje Ljungberg
M1	Effect of Prior Solid Organ Transplant on Localized RCC Outcomes by Treatment Type	Survivorship	Daniel Roadman
N1	KEYMAKER-U03 substudy 03C: Phase 1b/2 study of belzutifan plus zanzalintinib for recurrent clear cell renal cell carcinoma (RCC) during or after anti-PD-(L)1 therapy	Therapeutics	Brian Rini
N2	Strategic Trimodal Therapy Enhances Radiation-induced Abscopal Response in Renal Cancer	Therapeutics	Krishnendu Pal
N3	Outcomes of Patients with Fumarate Hydratase – Deficient Renal Cell Carcinoma Treated with Cabozantinib + Nivolumab	Therapeutics	Maria I. Carlo
N4	Nivolumab plus ipilimumab (NIVO+IPI) vs sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC): final analysis from the phase 3 CheckMate 214 trial	Therapeutics	Saby George
N5	Exploring the impact of combined anti-angiogenic and immune checkpoint inhibitors in clear cell renal cell carcinoma metastases	Therapeutics	Stefan Maksimovic
N6	Preliminary Phase 1 safety and antitumor activity of XmAb819, a first-in-class ENPP3 x CD3 bispecific antibody, in patients with advanced clear cell renal cell carcinoma (ccRCC)	Therapeutics	Sumanta Pal
N7	Cabozantinib in patients (pts) with non-locally pretreated brain metastases (BM) from renal cell carcinoma (RCC): Results from the multicenter CABRAMET phase II trial	Therapeutics	Sylvie Negrier
N8	A phase II study of neoadjuvant ivonescimab in patients with high-risk, localized RCC	Therapeutics	Wesley Yip
O1	Dietary fiber intake and gut microbial fiber fermentation capacity are associated with favorable clinical outcomes with immune checkpoint blockade (ICB) for renal cell carcinoma (RCC)	Translational Research	Brendan Guercio

POS #	PRESENTATION TITLE	TRACK	AUTHOR
O2	Molecular characteristics associated with papillary renal cell carcinoma tumor samples according to their diagnostic staging TNM classification	Translational Research	Juan Antonio Raygoza Garay
O3	Mitochondrial health as a biomarker of T cell fitness	Translational Research	Katy Beckermann
O4	Prognostic Signatures Associated with TP53 mutations in chromophobe renal cell carcinoma	Translational Research	Nathan Maulding
O5	NPRL2 loss silences STING signaling from genomic instability and promotes a CD8lowM2high microenvironment	Translational Research	Xiande Liu
O6	AI-Driven Multiplex Immunofluorescence Analysis of the Tumor Immune Microenvironment to Predict Immunotherapy Response in Clear Cell Renal Cell Carcinoma	Translational Research	Yuanquan Yang

Exhibit and Poster

Hall Hours

Friday, November 14

7:30AM-7:45PM


Saturday, November 15

7:30AM-11:50AM

EXHIBITOR LISTING

BOOTH

Aveo Oncology	103
BMS	101
Broad Institute	111
Eisai	107
Elekta	105
Exelixis	100
Merck & Co., Inc.	106 & 108
Oncorena	112
Pfizer	102
Telix	104
Xencor	110



Kidney Cancer Association (KCA) International Kidney Cancer Symposium 2025
November 13-15, 2025

Westin Westminster / Legacy Ballroom / Westminster, CO

V2 / Sh Job #112511

DRAWN BY:BJ

REVISION DATE:14/2025





See what this means
for your patients.

Go to **FOTIVDA.com** or scan the code



FOTIVDA is a registered trademark of AVEO Pharmaceuticals, Inc.
© 2024 AVEO Pharmaceuticals, Inc. All rights reserved. US-MAT-00205 01/24



Stay up to date with the data
INLYTA[®] (axitinib) + pembrolizumab



Scan to visit
INLYTAhcp.com

To learn more,
visit our booth



THANK YOU TO OUR INDUSTRY SPONSORS

SIGNATURE



PREMIER



TITLE



SUPPORTING



PARTICIPATING



IKCS Code of Conduct

We are committed to providing a safe, inclusive, and productive environment for all attendees. By attending, you agree to adhere to this Code of Conduct to ensure a positive experience for everyone.

CORE VALUES AND GOALS

At IKCS, we aim to foster a dynamic, multidisciplinary environment that explores current trends and future directions in kidney cancer. Our community, which includes leading experts from academia, clinical care, industry, and advocacy, is dedicated to exchanging innovative ideas and pushing boundaries to advance kidney cancer care.

EXPECTED BEHAVIOR

- Conduct yourself in a professional and respectful manner at all times.
- Treat all participants, including attendees, speakers, staff, and vendors, with courtesy and respect.
- Actively participate in sessions and discussions, contributing to a collaborative and inclusive atmosphere.
- Respect the views and opinions of others, even if they differ from your own.
- Follow all event-related instructions from staff and adhere to the guidelines set forth by the venue.

UNACCEPTABLE BEHAVIOR

- Harassment, discrimination, or intimidation of any kind, including but not limited to sexist, racist, or exclusionary comments or actions.
- Physical or verbal abuse of any participant, attendee, speaker, or staff member.
- Disruption of presentations, sessions, or other events organized by IKCSEU25.
- Inappropriate use of technology and social media, including the sharing of confidential or proprietary information without permission.
- Any other behavior that would be deemed unprofessional or inappropriate in a business or academic setting.

REPORTING PROCEDURES

If you experience or witness any unacceptable behavior, please report it as soon as possible. You can:

- Contact any of the Kidney Cancer Association (KCA) staff members directly.
- Email your concern to meetings@kidneycancer.org.

All reports will be treated seriously and investigated promptly. Your confidentiality will be respected to the fullest extent possible.

CONSEQUENCES

Participants who violate this Code of Conduct may be subject to appropriate action, including but not limited to:

- Warning the offender.
- Expulsion from the conference without a refund.
- Banning from future IKCS events.

CONTACTS FOR ASSISTANCE

For assistance or if you have any questions about the Code of Conduct, please reach out to any KCA staff member or email meetings@kidneycancer.org.



Listen to *Kidney Cancer Unfiltered*

We've got a PODCAST! Real experts, real patients, real stories, all of it completely unfiltered. Find *Kidney Cancer Unfiltered* on all major podcasting platforms and watch full episodes on YouTube.

**SCAN TO ACCESS THE
PODCAST**

IT'S ABOUT TIME



OPDIVO Qvantig™
nivolumab + hyaluronidase-nvhy
SUBCUTANEOUS INJECTION | 120 mg + 2,000 units / mL



Scan to learn more

Bristol Myers Squibb

© 2025 Bristol-Myers Squibb Company.
OPDIVO Qvantig™ and the related logo are
trademarks of Bristol-Myers Squibb Company.
1992-US-2500462 08/25



DISCOVER COLORADO SPRINGS

**Where mountain adventure
meets modern convenience**

Colorado Springs boasts over 500,000 square feet of flexible meeting space along with 300 days of sunshine and unbelievable mountain views. Here, you'll find the perfect blend of big-city amenities with a small-town feel. Allow our award-winning sales team to provide complimentary services that make planning your event a breeze.



Start planning today at VisitCOS.com



We Fund Research!

APPLICATIONS OPEN MARCH 2026

\$75,000 TRAILBLAZER & FOCUS AWARDS

The KCA is committed to supporting groundbreaking research that benefits people impacted by kidney cancer.



Scan QR code to donate today
Every dollar propels kidney cancer
research.



KidneyCancerAssociation®

The Kidney Cancer Association is a global community dedicated to serving and empowering patients and caregivers, and leading change through advocacy, research, and education in order to be the universal leader in finding a cure for kidney cancer.

KIDNEYCANCER.ORG

office@kidneycancer.org | 800-850-9132

International: +1847 332 1051

MAILING ADDRESS

2777 Allen Parkway, Suite 424

Houston, TX 77019

DONATION ADDRESS

PO Box 676226

Dallas, TX 75267-6226

HQ IN HOUSTON TEXAS

#UnstoppableTogether

@KidneyCancerAssociation | @KidneyCancer

